Page 8 - Pharma Stocks

Stocks to Watch on Apr 3, 2025: IT, auto, pharma, Central Bank, Muthoot Fin

Stocks to Watch on Apr 3, 2025: As the US imposed ;reciprocal tariffs' IT, Pharma and auto related stocks will be in focus

Closing Bell: Benchmarks rebound; Trump tariff hit auto stocks, PSBs outrun

Auto stocks, on the other hand, witnessed a sell-off after US President Donald Trump announced a 25 per cent tariff on imported cars and key auto parts, effective April 3

Here's why Marksans Pharma share was buzzing in trade on March 20

The products will be manufactured at the Verna, Goa facility, and will be marketed & distributed in Australian markets through the Marksans Pharma's subsidiary Nova Pharmaceuticals Australasia Pty

Marksans Pharma up 3% as arm secures marketing authorisation for Baclofen

The northward move in Marksans Pharma came after the company's wholly-owned subsidiary, Relonchem, received Marketing Authorisation for the product Baclofen 10 mg Tablets from UK MHRA

Here's why Zydus Lifesciences share price popped 3% in trade on March 19

The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg

Here's why Zydus Lifesciences share price was buzzing in trade on March 17

The uptick in the Zydus Life shares came after the company received final approval from the USFDA to manufacture Eluxadoline Tablets, 75 mg and 100 mg

Emcure Pharmaceuticals share gains on foraying into daily supplements space

The uptick in the Emcure Pharmaceuticals share price came after the company announced its entry into the daily supplements space with the expansion of its Arth range

Stocks to Watch: Adani Enterprises, Zomato, Swiggy, Cement, Pharma stocks

Stock market today: Pan-Indian average cement prices have risen for three consecutive months. In February, prices increased by ₹3 per 50 kg bag (up 1% M-o-M and 2% Y-o-Y) to ₹374 per bag

Defensive sector weightage in Nifty 50 declines to 15 year low

Underperforms in falling market for first time in over 20 years

Biocon share price up 2% as arm launches Yesintek in US; check details here

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available to patients in US

Zydus Lifesciences, Granules, Glenmark: Nifty Pharma up despite weak market

Nifty Pharma among others has gained 0.8 per cent in trade, logging an intra-day high at 20,550.6

Suven Pharma soars 14% on heavy volumes; surges 43% from January low

Suven Pharma is set to benefit from high-growth cutting-edge CDMO segments and its proven track record to drive traditional business.

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Suven Pharma, Divis, Syngene: Why Macquarie is betting big on Indian pharma

Pharma stocks list: Divis Labs share price rallied 1.9% intraday, Suven Pharma share price surged 4.6%, Blue Jet Healthcare share price added 4.9%, and Syngene International share price rose 1.5%

Pharma stocks plunge amid tariff concerns, but analysts see limited impact

Pharma stocks fell on Friday on concerns of tariff on imports

Nifty Pharma index slips 3%; Natco, Glenmark, Lupin, Laurus down up to 10%

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

PI Industries hits 52-week low; down 11% in one week on poor Q3 earnings

PI Industries' steady Q3FY25 performance, cautious near-term outlook, and portfolio challenges are likely to affect the business dynamics in FY26 and FY27, according to analysts.

FDC hits 52-week low, stock slips 9% on weak Q3 results

EBITDA for Q3FY25 was impacted by lower sales in export formulation biz, price reduction in the Electral range of products, driven by NLEM price revisions changes in the product mix, and higher cost.

Analysts bullish on Lupin after Q3; share pops 6%; Goldman Sachs ups target

Domestic, as well as global brokerages are optimistic about Lupin's future, citing strong earnings visibility and a promising product pipeline

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent